EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CD44 and its implication in neoplastic diseases

Yiming Xu, Ziyi Bai, Tianxia Lan, Chenying Fu, Ping Cheng

MedComm · 2024-06 · 5 (6)

DOI: 10.1002/mco2.554 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 23.05.2024. Verfasst von Yiming Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center f…. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 296 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD44, a nonkinase single span transmembrane glycoprotein, is a major cell surface receptor for many other extracellular matrix components as well as classic markers of cancer stem cells and immune cells. Through alternative splicing of CD44 gene, CD44 is divided into two isoforms, the standard isoform of CD44 (CD44s) and the variant isoform of CD44 (CD44v). Different isoforms of CD44 participate in regulating various signaling pathways, modulating cancer proliferation, invasion, metastasis, and drug resistance, with its aberrant expression and dysregulation contributing to tumor initiation and progression. However, CD44s and CD44v play overlapping or contradictory roles in tumor initiation and progression, which is not fully understood. Herein, we discuss the present understanding of the functional and structural roles of CD44 in the pathogenic mechanism of multiple cancers. The regulation functions of CD44 in cancers‐associated signaling pathways is summarized. Moreover, we provide an overview of the anticancer therapeutic strategies that targeting CD44 and preclinical and clinical trials evaluating the pharmacokinetics, efficacy, and drug‐related toxicity about CD44‐targeted therapies. This review provides up‐to‐date information about the roles of CD44 in neoplastic diseases, which may open new perspectives in the field of cancer treatment through targeting CD44.

Schlagwörter

Stichwörter der Autor:innen

CD44neoplastic diseasessignaling pathwaystherapeutic strategies

Autor:innen und Institutionen

  • Department of Biotherapy Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University Chengdu Sichuan…
  • Laboratory of Aging and Geriatric Medicine, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University Chengdu Sichuan China.
  • Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University Chengdu China.

Zitieren

APA

Xu, Y., Bai, Z., Lan, T., Fu, C., & Cheng, P. (2024). CD44 and its implication in neoplastic diseases. MedComm, 5(6). https://doi.org/10.1002/mco2.554

Vancouver

Xu Y, Bai Z, Lan T, Fu C, Cheng P. CD44 and its implication in neoplastic diseases. MedComm. 2024;5(6). doi:10.1002/mco2.554

BibTeX
@article{Xu2024,
  author = {Xu, Yiming and Bai, Ziyi and Lan, Tianxia and Fu, Chenying and Cheng, Ping},
  title = {CD44 and its implication in neoplastic diseases},
  journal = {MedComm},
  year = {2024},
  volume = {5},
  number = {6},
  doi = {10.1002/mco2.554}
}
Kostenlos starten →